Clinical trials
High Grade Glioma (III or IV) clinical trials
Below are recruiting high grade glioma (iii or iv) clinical trials, each written for real people, not researchers. We’re tracking 1,283 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05281406RecruitingPhase 2
Extra chemotherapy if tumor DNA stays positive after osimertinib
This Phase 2 trial tests whether adding chemotherapy can help people with EGFR-mutated lung cancer when their cancer-related blood test (liquid biopsy for EGFR DNA) is still positive after 3–4 weeks of starting osimertinib. It may help slow the cancer for longer by treating any remaining disease activity.
BerlinAges 18 years+ - NCT05283512Recruiting
IV versus drink fluids to protect kidneys after CT scan
This study compares giving fluids through a vein versus drinking fluids to lower the risk of sudden kidney injury after a CT scan with contrast dye. It focuses on adults with very poor kidney function who are scheduled for an elective CT scan.
Odense C, FynAges 18 years+ - NCT05284006Recruiting
Non-invasive tests for Morquio A
This trial studies Morquio A (MPS IVA) using non-invasive ways to measure how the body is working, and to better understand why the condition happens. If you have Morquio A, this may help researchers learn more and improve care.
Wilmington, DelawareAges Any age - NCT05293197RecruitingPhase 1
Safety study of repeated blood-brain barrier opening for pediatric brain tumors
This Phase 1 study tests whether a device can safely and repeatedly open the blood-brain barrier (a protective shield in the brain) in children with malignant brain tumors. It aims to help the tumor treatment work better while watching for safety issues.
ParisAges 5–17 - NCT05294471Recruiting
Automated MRI to measure liver fat and iron
This study uses an automated MRI scan to measure things in the liver, such as liver fat and iron levels. It may help researchers better understand liver changes and improve how these measurements are done.
Madison, WisconsinAges 7 years+ - NCT05296681RecruitingPhase 2
Probiotic trial to help irinotecan work better in metastatic colon cancer
This trial tests a “microbiome health” product (a probiotic-type supplement) to improve how well irinotecan chemotherapy works for people with metastatic colon cancer. It aims to support gut health so treatment can be delivered effectively.
Hamilton, New JerseyAges 18 years+ - NCT05296564RecruitingPhase 1/Phase 2
TCR cell therapy for NY-ESO-1 positive metastatic cancers
This study tests a customized immune-cell treatment made from your own T cells to attack cancers that have NY-ESO-1. It may help shrink tumors in people with metastatic or hard-to-treat cancer when other treatments have not worked.
JerusalemAges 18–70 - NCT05304442RecruitingPhase 3
IV iron for anemia from heavy uterine bleeding
This trial studies whether giving iron through a vein (IV) helps improve anemia caused by heavy uterine bleeding. You may join if you were treated in the emergency department, can go home, and can return for follow-up checks in the next several weeks.
Houston, TexasAges 18–65 - NCT05306899RecruitingPhase 3
IV ketamine for chronic daily headaches
This trial tests whether an IV dose of ketamine can reduce chronic daily headaches and is safe for people with this condition. It may help by lowering headache frequency and severity, but it also has several medicine and health-related safety checks.
Toronto, OntarioAges 18–75 - NCT05313165Recruiting
Stent procedure for poor blood flow in the leg ulcers and gangrene
This trial tests a new minimally invasive procedure (placing a small stent) to improve blood flow to a severely threatened foot or lower leg. It may help people whose ulcers or gangrene are not treatable with standard bypass or other surgeries.
La Jolla, CaliforniaAges 18–95 - NCT05317819RecruitingPhase 3
Test ADI-PEG 20 versus placebo for advanced liver cancer
This study tests whether ADI-PEG 20 helps people with advanced, unresectable hepatocellular carcinoma (liver cancer) who have high arginine levels. Participants get ADI-PEG 20 or a placebo to see which works better and improves outcomes.
ChanghuaAges 18–99 - NCT05318469RecruitingPhase 1/Phase 2
Ivermectin with immunotherapy for metastatic triple-negative breast cancer
This trial studies whether ivermectin, given together with immunotherapy (balstilimab or pembrolizumab), can help treat metastatic triple-negative breast cancer. It mainly looks at safety first, and may also explore how well the treatment works for people whose cancer has spread.
Los Angeles, CaliforniaAges 18 years+ - NCT05319639RecruitingPhase 1/Phase 2
Irinotecan plus immunotherapy for stomach cancer
This Phase I/II trial tests how well irinotecan combined with tislelizumab (an immunotherapy) treats advanced stomach or gastroesophageal junction adenocarcinoma. It mainly looks at safety and the best way to use this combination, and may help shrink tumors or slow disease growth.
Fuzhou, FujianAges 18–75 - NCT05332925Recruiting
Tumor samples grown in dishes to predict immunotherapy response
This study takes small biopsy samples of your lung cancer and grows them in a dish to predict how well immunotherapy will work. If you qualify, you’ll receive standard immunotherapy (anti-PD-1/L1, with or without anti-CTLA-4), and the results from the dish-grown tumors will be compared to your real-world response.
Fairway, KansasAges 18–110 - NCT05340465RecruitingPhase 2
IV iron in preterm babies to reduce blood transfusions
This Phase 2 study tests whether giving a specific IV iron (darbe plus IV iron) can help preterm babies need fewer blood transfusions while still keeping their iron levels in a safe range. It focuses on babies in the NICU who were born early, and it compares transfusion use and iron sufficiency over time.
Seattle, WashingtonAges Up to 3 days - NCT05348876RecruitingPhase 4
Darolutamide plus standard hormone therapy for high-risk prostate cancer
This trial studies how safe darolutamide is and how well it works when added to standard hormone therapy for men with high-risk, non-metastatic prostate cancer that is no longer responding to hormone treatment. It may help slow prostate cancer growth and reduce prostate-specific antigen (PSA) rises in real-world care.
Vijayawada, Andhra PradeshAges 18 years+ - NCT05377034RecruitingPhase 2
Y-90 and immunotherapy vs Y-90 plus placebo for liver cancer
This phase 2 study tests whether adding immunotherapy drugs (atezolizumab and bevacizumab) after Y-90 treatment works better and is safe compared with Y-90 followed by placebo. It is for people with liver cancer that has not spread outside the liver but is difficult to treat.
BeijingAges 21–99 - NCT05377047Recruiting
Targeted radiation for limited recurrent breast cancer spread
This trial tests whether a precise form of high-dose radiation can control up to 1–5 breast cancer metastases (spread) in a few body areas. It may help by focusing treatment only on visible spots while limiting radiation to the rest of the body.
Gothenburg, Västra GötalandsregionenAges 18 years+ - NCT05379595RecruitingPhase 1/Phase 2
Amivantamab for advanced colon or rectal cancer with specific tumor traits
This Phase 1/2 study tests amivantamab alone or combined with standard chemotherapy to treat advanced or metastatic colon or rectal cancer. You may be able to join if your tumor has the right genetic profile (typically “wild-type” for certain genes and no HER2 amplification) and your cancer has measurable or biopsy-able lesions.
Birmingham, AlabamaAges 18 years+ - NCT05385549RecruitingPhase 2
5-Year imatinib after GIST surgery for high-risk patients
This study looks at taking imatinib (a targeted anti-cancer pill) for 5 years after your GIST tumor has been fully removed. It is meant to lower the chance that GIST comes back in people considered “high risk.”
Seoul, SeoulAges 20 years+ - NCT05386043Recruiting
Study brain tumor testing with MRI and extra tissue samples
This study looks at how brain tumors look on MRI and what biopsy tissue shows, using samples taken during planned surgery. It may help improve understanding of tumor biology and future treatment planning.
Indianapolis, IndianaAges 18 years+ - NCT05394103RecruitingPhase 1/Phase 2
Testing a targeted pill for hard-to-treat solid tumors
This trial tests a new medicine (Q901) that targets a specific cell-control pathway to treat advanced cancers that have stopped responding to standard care. It’s mainly for people with certain solid tumor cancers, aiming to see whether the drug can shrink tumors or control disease.
Phoenix, ArizonaAges 18 years+ - NCT05398302RecruitingPhase 1
Biopsies during prostate cancer treatment to study resistance
This early study uses image-guided biopsies (small tissue samples taken with imaging) to learn why metastatic prostate cancer may stop responding to PSMA radioligand therapy. The results may help doctors understand resistance and improve future treatments.
Los Angeles, CaliforniaAges Any age - NCT05410717RecruitingPhase 1
CAR-NK cell therapy for certain solid tumors
This early-phase trial tests a lab-made immune cell treatment for advanced solid tumors that show specific targets (including Claudin 6, GPC3, Mesothelin, or AXL). It may help the immune system better recognize and kill tumor cells, but eligibility depends on test results and your overall health.
Guangzhou, GuangdongAges 18–75
Hear when a new High Grade Glioma (III or IV) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for high grade glioma (iii or iv)?
- Yes. Clin2 currently lists 1,283 recruiting high grade glioma (iii or iv) studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a high grade glioma (iii or iv) trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a high grade glioma (iii or iv) trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.